Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy
Abstract Background Paradoxically, Helicobacter pylori–positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP–negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favora...
Gespeichert in:
| Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 2022-08, Vol.114 (8), p.1149-1158 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1158 |
|---|---|
| container_issue | 8 |
| container_start_page | 1149 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 114 |
| creator | Koizumi, Yuka Ahmad, Sheny Ikeda, Miyuki Yashima-Abo, Akiko Espina, Ginny Sugimoto, Ryo Sugai, Tamotsu Iwaya, Takeshi Tamura, Gen Koeda, Keisuke Liotta, Lance A Takahashi, Fumiaki Nishizuka, Satoshi S |
| description | Abstract
Background
Paradoxically, Helicobacter pylori–positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP–negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favorable outcome.
Methods
A total of 658 advanced gastric cancer patients who underwent gastrectomy were enrolled. HP infection, mismatch repair, programmed death–ligand 1 (PD-L1) and CD4/CD8 proteins, and microsatellite instability were analyzed. Overall survival (OS) and relapse-free survival (RFS) rates were analyzed after stratifying clinicopathological factors. Cox proportional hazards regression analysis was performed to identify independent prognostic factors.
Results
Among 491 patients that were analyzed, 175 (36%) and 316 (64%) patients were HP+ and HP−, respectively. Analysis of RFS indicated an interaction of HP status among the subgroups for S-1 dose (Pinteraction = .049) and PD-L1 (P = .02). HP+ patients in the PD-L1- group had statistically higher 5-year OS and RFS than HP- patients (81% vs 68%; P = .0011; hazard ratio [HR] = 0.48, 95% confidence interval [CI] = 0.303 to 0.751, and 76% vs 63%; P = .001; HR = 0.508, 95% CI = 0.335 to 0.771, respectively). The 5-year OS and RFS was also statistically higher for HP+ compared with HP- patients in the "PD-L1- and S-1–r educed" group (86% vs 46%; P = .001; HR = 0.205, 95% CI = 0.07 to 0.602, and 83% vs 34%; P = .001; HR = 0.190, 95% CI = 0.072 to 0.498, respectively). Thus, HP status was identified as one of the most potentially important independent factors to predict prolonged survival.
Conclusion
This retrospective study suggests that an HP-modulated host immune system may contribute to prolonged survival in the absence of immune escape mechanisms of gastric cancer. |
| doi_str_mv | 10.1093/jnci/djac085 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jnci/djac085</oup_id><sourcerecordid>2701638929</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-6511c28f7f816acf286528111c320782164d6dfa55b8b05d9a055ad4a3c1a3973</originalsourceid><addsrcrecordid>eNp9kcFrFDEUxoModq3ePEvAQz04NskkmcxFKEvtFioKKh7D2yTjZpiZjEmmsP99U3Yt1oPv8uC93_v4Hh9Cryn5QElbn_eT8ee2B0OUeIJWlEtSMUrEU7QihDWVUg0_QS9S6kmplvHn6KQWvG5EK1fIbdzgTdiCyS7ieT-E6PHnYJcBsrN4E1LG1-O4TD7vsZ_wFaQcvcFrmEw5-ArZuykn_NPnHf5WUXxh--UWpozXOzeGvHMR5v1L9KyDIblXx36Kfny6_L7eVDdfrq7XFzeV4ZznSgpKDVNd0ykqwXRMScEULcOakUYxKrmVtgMhtmpLhG2BCAGWQ20o1G1Tn6KPB9152Y7OmmItwqDn6EeIex3A68ebye_0r3Cr21oS3rAi8O4oEMPvxaWsR5-MGwaYXFiSZsWQUEwJVdC3_6B9WOJU3tOsIVTWqmVtod4fKBNDStF1D2Yo0ff56fv89DG_gr_5-4EH-E9gBTg7AGGZ_y91B2wcpV4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2701638929</pqid></control><display><type>article</type><title>Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Koizumi, Yuka ; Ahmad, Sheny ; Ikeda, Miyuki ; Yashima-Abo, Akiko ; Espina, Ginny ; Sugimoto, Ryo ; Sugai, Tamotsu ; Iwaya, Takeshi ; Tamura, Gen ; Koeda, Keisuke ; Liotta, Lance A ; Takahashi, Fumiaki ; Nishizuka, Satoshi S</creator><creatorcontrib>Koizumi, Yuka ; Ahmad, Sheny ; Ikeda, Miyuki ; Yashima-Abo, Akiko ; Espina, Ginny ; Sugimoto, Ryo ; Sugai, Tamotsu ; Iwaya, Takeshi ; Tamura, Gen ; Koeda, Keisuke ; Liotta, Lance A ; Takahashi, Fumiaki ; Nishizuka, Satoshi S ; Northern Japan Gastric Cancer Study Consortium ; the Northern Japan Gastric Cancer Study Consortium</creatorcontrib><description>Abstract
Background
Paradoxically, Helicobacter pylori–positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP–negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favorable outcome.
Methods
A total of 658 advanced gastric cancer patients who underwent gastrectomy were enrolled. HP infection, mismatch repair, programmed death–ligand 1 (PD-L1) and CD4/CD8 proteins, and microsatellite instability were analyzed. Overall survival (OS) and relapse-free survival (RFS) rates were analyzed after stratifying clinicopathological factors. Cox proportional hazards regression analysis was performed to identify independent prognostic factors.
Results
Among 491 patients that were analyzed, 175 (36%) and 316 (64%) patients were HP+ and HP−, respectively. Analysis of RFS indicated an interaction of HP status among the subgroups for S-1 dose (Pinteraction = .049) and PD-L1 (P = .02). HP+ patients in the PD-L1- group had statistically higher 5-year OS and RFS than HP- patients (81% vs 68%; P = .0011; hazard ratio [HR] = 0.48, 95% confidence interval [CI] = 0.303 to 0.751, and 76% vs 63%; P = .001; HR = 0.508, 95% CI = 0.335 to 0.771, respectively). The 5-year OS and RFS was also statistically higher for HP+ compared with HP- patients in the "PD-L1- and S-1–r educed" group (86% vs 46%; P = .001; HR = 0.205, 95% CI = 0.07 to 0.602, and 83% vs 34%; P = .001; HR = 0.190, 95% CI = 0.072 to 0.498, respectively). Thus, HP status was identified as one of the most potentially important independent factors to predict prolonged survival.
Conclusion
This retrospective study suggests that an HP-modulated host immune system may contribute to prolonged survival in the absence of immune escape mechanisms of gastric cancer.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/djac085</identifier><identifier>PMID: 35437596</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>B7-H1 Antigen - metabolism ; Cancer ; CD4 antigen ; CD8 antigen ; Chemotherapy ; Chemotherapy, Adjuvant ; Confidence intervals ; Gastrectomy ; Gastric cancer ; Hazard identification ; Health hazards ; Helicobacter pylori ; Humans ; Immune system ; Medical prognosis ; Microsatellite instability ; Mismatch repair ; Neoplasm Recurrence, Local - pathology ; PD-L1 protein ; Prognosis ; Regression analysis ; Retrospective Studies ; Stability analysis ; Statistical analysis ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - surgery ; Subgroups ; Survival</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2022-08, Vol.114 (8), p.1149-1158</ispartof><rights>The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com 2022</rights><rights>The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><rights>The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-6511c28f7f816acf286528111c320782164d6dfa55b8b05d9a055ad4a3c1a3973</citedby><cites>FETCH-LOGICAL-c444t-6511c28f7f816acf286528111c320782164d6dfa55b8b05d9a055ad4a3c1a3973</cites><orcidid>0000-0001-9201-1089 ; 0000-0001-9178-790X ; 0000-0002-9486-0823 ; 0000-0001-8341-5700 ; 0000-0002-4896-3557 ; 0000-0001-8440-0594</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35437596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koizumi, Yuka</creatorcontrib><creatorcontrib>Ahmad, Sheny</creatorcontrib><creatorcontrib>Ikeda, Miyuki</creatorcontrib><creatorcontrib>Yashima-Abo, Akiko</creatorcontrib><creatorcontrib>Espina, Ginny</creatorcontrib><creatorcontrib>Sugimoto, Ryo</creatorcontrib><creatorcontrib>Sugai, Tamotsu</creatorcontrib><creatorcontrib>Iwaya, Takeshi</creatorcontrib><creatorcontrib>Tamura, Gen</creatorcontrib><creatorcontrib>Koeda, Keisuke</creatorcontrib><creatorcontrib>Liotta, Lance A</creatorcontrib><creatorcontrib>Takahashi, Fumiaki</creatorcontrib><creatorcontrib>Nishizuka, Satoshi S</creatorcontrib><creatorcontrib>Northern Japan Gastric Cancer Study Consortium</creatorcontrib><creatorcontrib>the Northern Japan Gastric Cancer Study Consortium</creatorcontrib><title>Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Abstract
Background
Paradoxically, Helicobacter pylori–positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP–negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favorable outcome.
Methods
A total of 658 advanced gastric cancer patients who underwent gastrectomy were enrolled. HP infection, mismatch repair, programmed death–ligand 1 (PD-L1) and CD4/CD8 proteins, and microsatellite instability were analyzed. Overall survival (OS) and relapse-free survival (RFS) rates were analyzed after stratifying clinicopathological factors. Cox proportional hazards regression analysis was performed to identify independent prognostic factors.
Results
Among 491 patients that were analyzed, 175 (36%) and 316 (64%) patients were HP+ and HP−, respectively. Analysis of RFS indicated an interaction of HP status among the subgroups for S-1 dose (Pinteraction = .049) and PD-L1 (P = .02). HP+ patients in the PD-L1- group had statistically higher 5-year OS and RFS than HP- patients (81% vs 68%; P = .0011; hazard ratio [HR] = 0.48, 95% confidence interval [CI] = 0.303 to 0.751, and 76% vs 63%; P = .001; HR = 0.508, 95% CI = 0.335 to 0.771, respectively). The 5-year OS and RFS was also statistically higher for HP+ compared with HP- patients in the "PD-L1- and S-1–r educed" group (86% vs 46%; P = .001; HR = 0.205, 95% CI = 0.07 to 0.602, and 83% vs 34%; P = .001; HR = 0.190, 95% CI = 0.072 to 0.498, respectively). Thus, HP status was identified as one of the most potentially important independent factors to predict prolonged survival.
Conclusion
This retrospective study suggests that an HP-modulated host immune system may contribute to prolonged survival in the absence of immune escape mechanisms of gastric cancer.</description><subject>B7-H1 Antigen - metabolism</subject><subject>Cancer</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Confidence intervals</subject><subject>Gastrectomy</subject><subject>Gastric cancer</subject><subject>Hazard identification</subject><subject>Health hazards</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Immune system</subject><subject>Medical prognosis</subject><subject>Microsatellite instability</subject><subject>Mismatch repair</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>PD-L1 protein</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Stability analysis</subject><subject>Statistical analysis</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - surgery</subject><subject>Subgroups</subject><subject>Survival</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFrFDEUxoModq3ePEvAQz04NskkmcxFKEvtFioKKh7D2yTjZpiZjEmmsP99U3Yt1oPv8uC93_v4Hh9Cryn5QElbn_eT8ee2B0OUeIJWlEtSMUrEU7QihDWVUg0_QS9S6kmplvHn6KQWvG5EK1fIbdzgTdiCyS7ieT-E6PHnYJcBsrN4E1LG1-O4TD7vsZ_wFaQcvcFrmEw5-ArZuykn_NPnHf5WUXxh--UWpozXOzeGvHMR5v1L9KyDIblXx36Kfny6_L7eVDdfrq7XFzeV4ZznSgpKDVNd0ykqwXRMScEULcOakUYxKrmVtgMhtmpLhG2BCAGWQ20o1G1Tn6KPB9152Y7OmmItwqDn6EeIex3A68ebye_0r3Cr21oS3rAi8O4oEMPvxaWsR5-MGwaYXFiSZsWQUEwJVdC3_6B9WOJU3tOsIVTWqmVtod4fKBNDStF1D2Yo0ff56fv89DG_gr_5-4EH-E9gBTg7AGGZ_y91B2wcpV4</recordid><startdate>20220808</startdate><enddate>20220808</enddate><creator>Koizumi, Yuka</creator><creator>Ahmad, Sheny</creator><creator>Ikeda, Miyuki</creator><creator>Yashima-Abo, Akiko</creator><creator>Espina, Ginny</creator><creator>Sugimoto, Ryo</creator><creator>Sugai, Tamotsu</creator><creator>Iwaya, Takeshi</creator><creator>Tamura, Gen</creator><creator>Koeda, Keisuke</creator><creator>Liotta, Lance A</creator><creator>Takahashi, Fumiaki</creator><creator>Nishizuka, Satoshi S</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9201-1089</orcidid><orcidid>https://orcid.org/0000-0001-9178-790X</orcidid><orcidid>https://orcid.org/0000-0002-9486-0823</orcidid><orcidid>https://orcid.org/0000-0001-8341-5700</orcidid><orcidid>https://orcid.org/0000-0002-4896-3557</orcidid><orcidid>https://orcid.org/0000-0001-8440-0594</orcidid></search><sort><creationdate>20220808</creationdate><title>Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy</title><author>Koizumi, Yuka ; Ahmad, Sheny ; Ikeda, Miyuki ; Yashima-Abo, Akiko ; Espina, Ginny ; Sugimoto, Ryo ; Sugai, Tamotsu ; Iwaya, Takeshi ; Tamura, Gen ; Koeda, Keisuke ; Liotta, Lance A ; Takahashi, Fumiaki ; Nishizuka, Satoshi S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-6511c28f7f816acf286528111c320782164d6dfa55b8b05d9a055ad4a3c1a3973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>B7-H1 Antigen - metabolism</topic><topic>Cancer</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Confidence intervals</topic><topic>Gastrectomy</topic><topic>Gastric cancer</topic><topic>Hazard identification</topic><topic>Health hazards</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Immune system</topic><topic>Medical prognosis</topic><topic>Microsatellite instability</topic><topic>Mismatch repair</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>PD-L1 protein</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Stability analysis</topic><topic>Statistical analysis</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - surgery</topic><topic>Subgroups</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koizumi, Yuka</creatorcontrib><creatorcontrib>Ahmad, Sheny</creatorcontrib><creatorcontrib>Ikeda, Miyuki</creatorcontrib><creatorcontrib>Yashima-Abo, Akiko</creatorcontrib><creatorcontrib>Espina, Ginny</creatorcontrib><creatorcontrib>Sugimoto, Ryo</creatorcontrib><creatorcontrib>Sugai, Tamotsu</creatorcontrib><creatorcontrib>Iwaya, Takeshi</creatorcontrib><creatorcontrib>Tamura, Gen</creatorcontrib><creatorcontrib>Koeda, Keisuke</creatorcontrib><creatorcontrib>Liotta, Lance A</creatorcontrib><creatorcontrib>Takahashi, Fumiaki</creatorcontrib><creatorcontrib>Nishizuka, Satoshi S</creatorcontrib><creatorcontrib>Northern Japan Gastric Cancer Study Consortium</creatorcontrib><creatorcontrib>the Northern Japan Gastric Cancer Study Consortium</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koizumi, Yuka</au><au>Ahmad, Sheny</au><au>Ikeda, Miyuki</au><au>Yashima-Abo, Akiko</au><au>Espina, Ginny</au><au>Sugimoto, Ryo</au><au>Sugai, Tamotsu</au><au>Iwaya, Takeshi</au><au>Tamura, Gen</au><au>Koeda, Keisuke</au><au>Liotta, Lance A</au><au>Takahashi, Fumiaki</au><au>Nishizuka, Satoshi S</au><aucorp>Northern Japan Gastric Cancer Study Consortium</aucorp><aucorp>the Northern Japan Gastric Cancer Study Consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>2022-08-08</date><risdate>2022</risdate><volume>114</volume><issue>8</issue><spage>1149</spage><epage>1158</epage><pages>1149-1158</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><abstract>Abstract
Background
Paradoxically, Helicobacter pylori–positive (HP+) advanced gastric cancer patients have a better prognosis than those who are HP–negative (HP-). Immunologic and statistical analyses can be used to verify whether systemic mechanisms modulated by HP are involved in this more favorable outcome.
Methods
A total of 658 advanced gastric cancer patients who underwent gastrectomy were enrolled. HP infection, mismatch repair, programmed death–ligand 1 (PD-L1) and CD4/CD8 proteins, and microsatellite instability were analyzed. Overall survival (OS) and relapse-free survival (RFS) rates were analyzed after stratifying clinicopathological factors. Cox proportional hazards regression analysis was performed to identify independent prognostic factors.
Results
Among 491 patients that were analyzed, 175 (36%) and 316 (64%) patients were HP+ and HP−, respectively. Analysis of RFS indicated an interaction of HP status among the subgroups for S-1 dose (Pinteraction = .049) and PD-L1 (P = .02). HP+ patients in the PD-L1- group had statistically higher 5-year OS and RFS than HP- patients (81% vs 68%; P = .0011; hazard ratio [HR] = 0.48, 95% confidence interval [CI] = 0.303 to 0.751, and 76% vs 63%; P = .001; HR = 0.508, 95% CI = 0.335 to 0.771, respectively). The 5-year OS and RFS was also statistically higher for HP+ compared with HP- patients in the "PD-L1- and S-1–r educed" group (86% vs 46%; P = .001; HR = 0.205, 95% CI = 0.07 to 0.602, and 83% vs 34%; P = .001; HR = 0.190, 95% CI = 0.072 to 0.498, respectively). Thus, HP status was identified as one of the most potentially important independent factors to predict prolonged survival.
Conclusion
This retrospective study suggests that an HP-modulated host immune system may contribute to prolonged survival in the absence of immune escape mechanisms of gastric cancer.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>35437596</pmid><doi>10.1093/jnci/djac085</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9201-1089</orcidid><orcidid>https://orcid.org/0000-0001-9178-790X</orcidid><orcidid>https://orcid.org/0000-0002-9486-0823</orcidid><orcidid>https://orcid.org/0000-0001-8341-5700</orcidid><orcidid>https://orcid.org/0000-0002-4896-3557</orcidid><orcidid>https://orcid.org/0000-0001-8440-0594</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 2022-08, Vol.114 (8), p.1149-1158 |
| issn | 0027-8874 1460-2105 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9360472 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | B7-H1 Antigen - metabolism Cancer CD4 antigen CD8 antigen Chemotherapy Chemotherapy, Adjuvant Confidence intervals Gastrectomy Gastric cancer Hazard identification Health hazards Helicobacter pylori Humans Immune system Medical prognosis Microsatellite instability Mismatch repair Neoplasm Recurrence, Local - pathology PD-L1 protein Prognosis Regression analysis Retrospective Studies Stability analysis Statistical analysis Stomach Neoplasms - drug therapy Stomach Neoplasms - metabolism Stomach Neoplasms - surgery Subgroups Survival |
| title | Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A51%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Helicobacter%20pylori%20Modulated%20Host%20Immunity%20in%20Gastric%20Cancer%20Patients%20With%20S-1%20Adjuvant%20Chemotherapy&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Koizumi,%20Yuka&rft.aucorp=Northern%20Japan%20Gastric%20Cancer%20Study%20Consortium&rft.date=2022-08-08&rft.volume=114&rft.issue=8&rft.spage=1149&rft.epage=1158&rft.pages=1149-1158&rft.issn=0027-8874&rft.eissn=1460-2105&rft_id=info:doi/10.1093/jnci/djac085&rft_dat=%3Cproquest_pubme%3E2701638929%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2701638929&rft_id=info:pmid/35437596&rft_oup_id=10.1093/jnci/djac085&rfr_iscdi=true |